We conclude that, compared with IgG-only formulations which did not improve survival rates in patients with sepsis [47–49], treatment with IgM- and IgA-enriched immunoglobulins is very likely associated with a reduction in mortality and morbidity in terms of length of ventilatory support, length of ICU stay, and risk of secondary infectious complications [50–52, 71]. The gene discussed is CD79A; the disease is Sepsis.